Dova Pharmaceuticals Follow-On Offering
2/28/2018

Davis Polk advised the joint book-running managers in connection with the $80 million public offering of common stock of Dova Pharmaceuticals, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “DOVA.”

Based in Durham, North Carolina, Dova is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count.

The Davis Polk corporate team included partner Deanna L. Kirkpatrick and associates Milson C. Yu, Mahfouz Basith and Leigh Katz. Counsel David R. Bauer and associate Paul S. Lee provided intellectual property and technology advice. Partner Rachel D. Kleinberg and associate Liang Zhang provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and Northern California offices.